7
Dec

Jefferson Breast Cancer Researcher Named Margaret Q. Landenberger Professor

Nicole Simone, MD, has been named the Margaret Q. Landenberger Professor. The professorship, which focuses on breast cancer research, was established in 2006 by the Margaret Q. Landenberger Research Foundation. Dr. Simone will be the second holder of the professorship. “Dr. Simone is a cancer research pioneer who has dedicated her entire career to discovering …

9
Mar

Two Drexel University College of Medicine Professors Receive Grants Through Statewide Refunds for Breast Cancer Research Campaign

The Pennsylvania Breast Cancer Coalition recently awarded two Drexel University College of Medicine researchers (and Sidney Kimmel Cancer Center Members) grants from its statewide Refunds for Breast Cancer Research campaign. Alessandro Fatatis, MD, PhD, professor in the Departments of Pharmacology & Physiology and Pathology & Laboratory Medicine, and Mauricio Reginato, PhD, associate professor in the …

7
Jan

Hold Your Breath to Protect Your Heart

A recent article in the Practical Radiation Oncology was highlighted in Eureka Alerts. The research, performed by members of the Department of Radiation Oncology and the Sidney Kimmel Cancer Center of Thomas Jefferson University, indicated the importance of breathing control during radiation therapy for left breast cancer in protecting the heart from radiation exposure. Harriet …

9
Sep

KCC Researchers Awarded $480,000 from Breast Cancer Research Foundation

The Breast Cancer Research Foundation recently announced that Dr. Richard Pestell and Dr. Andrew Quong received unanimous approval for studies in breast cancer, the second most prevalent cancer-related cause of death in women in the United States. Beginning October 1, 2013, Dr. Pestell will receive $240,000 to continue the “Molecular Genetic determinants of Breast Cancer …

23
Aug

Researchers Find New Clues to Treat Rare and Aggressive Inflammatory Breast Cancer

A study led by investigators from Thomas Jefferson University’s Kimmel Cancer Center has discovered molecular clues that may help physicians therapeutically target inflammatory breast cancer (IBC), a highly aggressive form of breast cancer. Their study, reported in the June 21 online issue of Breast Cancer Research and Treatment, identified two molecules (ALK and FAK1) involved in the …

23
Aug

Researchers Discover Molecule That Drives Aggressive Breast Cancer

Recent studies by researchers at Thomas Jefferson University’s Kimmel Cancer Center have shown a gene known to coordinate initial development of the eye (EYA1) is a powerful breast tumor promoter in mice. The gene EYA1 was also shown to be overexpressed in a genetic breast cancer subtype called luminal B. The scientists found that excess …

15
Jul

Ladies of Port Richmond Featured in Inquirer

Mary Louise Leuters is a two-time breast cancer survivor and president of the Ladies of Port Richmond, a local group of breast cancer survivors who have raised over $400,000 for breast cancer research in the last nine years.Nearly 300,000 American women will be diagnosed with breast cancer this year, and 40,000 will die from it, …

12
Feb

Massimo Cristofanilli, M.D., Appointed Director of the Jefferson Breast Care Center

Massimo Cristofanilli, M.D., FACP, an internationally renowned breast cancer researcher and clinician, has been appointed Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals. With more than 25 years of clinical, basic science and educational experience, Dr. Cristofanilli will also serve as Deputy Director of …

12
Feb

Jefferson Opens Calorie Restriction Trial for Early Stage Breast Cancer Patients on Radiation Therapy

Jefferson’s Kimmel Cancer Center will begin a first-of-its-kind clinical trial that uses calorie restriction to help treat early stage breast cancer patients undergoing radiation therapy. Evidence suggests that reducing patients’ calorie intake could help shrink tumors and improve survival because it enhances the effectiveness of radiation therapy, the team explains in a recent review published …

20
Sep

Tissue around tumor holds key to fighting triple negative breast cancer

A natural substance found in the surrounding tissue of a tumor may be a promising weapon to stop triple negative breast cancer from metastasizing. A preclinical study published in PLOS ONE September 19 by Thomas Jefferson University researchers found that decorin, a well-studied protein known to help halt tumor growth, induces a series of tumor …

26
Jul

Breast Cancer Patients Who Lack RB Gene Respond Better to Neoadjuvant Chemotherapy

Breast cancer patients whose tumors lacked the retinoblastoma tumor suppressor gene (RB) had an improved pathological response to neoadjuvant chemotherapy, researchers at Thomas Jefferson University Hospital and the Kimmel Cancer Center at Jefferson report in a retrospective study published in a recent online issue of Clinical Cancer Research. Many breast cancer patients undergo neoadjuvant therapy …

14
Jun

How Aging Normal Cells Fuel Tumor Growth and Metastasis

It has long been known that cancer is a disease of aging, but a molecular link between the two has remained elusive. Now, researchers at the Kimmel Cancer Center at Jefferson (KCC) have shown that senescence (aging cells which lose their ability to divide) and autophagy (self-eating or self-cannibalism) in the surrounding normal cells of …

13
Jun

HIV Drug May Slow Down Metastatic Triple-Negative Breast Cancer

Researchers at the Kimmel Cancer Center, led by Dr. Richard G. Pestell have discovered that FDA-approved HIV drugs may stop triple-negative breast cancer from spreading to other organs in pre-clinical models. These results were originally reported in Cancer Research. Recent articles about this discovery have also appeared in NewsWise and the Philadelphia Inquirer.

7
Jun

HIV drug may slow down metastatic breast cancer

The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research. Such drugs target the HIV receptor CCR5, which the virus uses to enter and infect host cells, and …

3
Apr

AACR: Eliminating the ‘Good Cholesterol’ Receptor May Fight Breast Cancer

CHICAGO— Removing a lipoprotein receptor known as SR-BI may help protect against breast cancer, as suggested by new findings presented at the American Association for Cancer Research Annual Meeting 2012 by Jefferson’s Kimmel Cancer Center researchers. In vitro and mouse studies revealed that depletion of the SR-BI resulted in a decrease in breast cancer cell …

20
Mar

Biomarker Links Clinical Outcome with New Model of Lethal Tumor Metabolism

Researchers at the Kimmel Cancer Center at Jefferson have demonstrated for the first time that the metabolic biomarker MCT4 directly links clinical outcomes with a new model of tumor metabolism that has patients “feeding” their cancer cells.  Their findings were published online March 15 in Cell Cycle. To validate the prognostic value of the biomarker, …

15
Feb

Taxpayers Give Back for Cancer: Jefferson Researcher Awarded ‘Refunds for Research’ Grant

Takemi Tanaka, Ph.D., of Thomas Jefferson University’s School of Pharmacy and the Kimmel Cancer Center, received a $50,000 grant toward her breast cancer research, as part of the Pennsylvania Breast Cancer Coalition’s (PBCC) “Refunds for Breast and Cervical Cancer Research” initiative. The PBCC’s grants are made possible through contributions from state taxpayers who choose to …

7
Feb

Drugs targeting chromosomal instability may fight a particular breast cancer subtype

Another layer in breast cancer genetics has been peeled back. A team of researchers at Jefferson’s Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation …

13
Dec

Loss of RB in Triple Negative Breast Cancer Associated with Favorable Clinical Outcome

Researchers at the Thomas Jefferson University Hospital and Kimmel Cancer Center at Jefferson have shown that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is associated with better clinical outcomes. This is a new marker to identify the subset of these patients who may respond positively to chemotherapy. Today, …

31
Oct

Gordon Schwartz, M.D., Nominated to National Accreditation Program for Breast Centers Board

Gordon F. Schwartz, MD, MBA, FACS, director of the Jefferson Breast Care Center, will represent the American Society of Breast Disease on the board of the National Accreditation Program for Breast Centers (NAPBC). The NAPBC is a consortium of national, professional organizations dedicated to the improvement of the quality of care and the monitoring of …

Page 1 of 3